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Olmesartan for the delay  
or prevention of microalbuminuria 
in type 2 diabetes
Haller et al., N Engl J Med 2011; 364: 907–917; doi:10.1056/NEJMoa1007994
Treatment of diabetic nephropathy with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers is established, 
but prevention of diabetic nephropathy using similar agents has 
not been investigated to the same extent. Haller et al. conducted a 
study that randomized 4499 patients with type 2 diabetes mellitus 
to receive 40 mg/d olmesartan or placebo. Patients had normoalbu-
minuria at screening. Patients were followed for microalbuminu-
ria, confirmed by at least one additional positive test within 2 
weeks. Patient characteristics of the two treatment arms were well 
balanced. However, the group randomized to olmesartan had a 
slightly greater body mass index, systolic blood pressure, and uri-
nary albumin–creatinine ratio at baseline. Over a 3.2-year median 
follow-up, 8.2% of patients in the olmesartan group developed 
microalbuminuria, whereas 9.8% of patients developed microalbu-
minuria in the placebo group. After adjustment for the baseline 
differences, the hazard ratio became 0.75 (95.1% confidence inter-
val 0.62–0.92). The benefit of olmesartan therapy was strongest 
in patients with baseline systolic blood pressure greater than 135 
mm Hg, glycated hemoglobin less than 7.3%, glomerular filtration 
rate less than 83.79 ml/min, and urinary albumin–creatinine ratio 
greater than 4. No patients developed end-stage renal disease. The 
same number of patients in each group experienced a doubling 
of serum creatinine (n = 23). With respect to cardiovascular end 
points, the proportion of patients reaching the composite of cardi-
ovascular event or cardiovascular death was similar in both groups 
(4.3% and 4.2%, olmesartan and placebo groups, respectively).
This trial supports the use of olmesartan to prevent the develop-
ment of microalbuminuria in patients with type 2 diabetes mellitus. 
However, the unexpected finding of greater risk of cardiovascular 
death deserves further consideration. Although the possibility of 
the small number of events resulting in a type II statistical error is 
strong, further analyses of the database and studies are warranted, 
given the importance of this potential safety signal.
Lynda Szczech
Effect of paricalcitol and calcitriol 
on aortic wall remodeling in 
un inephrectomized ApoE 
knockout mice
Becker et al., Am J Physiol Renal Physiol 2011; 300: F772–F782; doi:10.1152/
ajprenal.00042.2010
Vascular calcification is a known complication of calcitriol 
therapy in uremic patients, even in children. On the other hand, 
vitamin D receptor (VDR) activators have been reported to 
upregulate the calcification inhibitor matrix Gla protein (MGP) 
and the synthesis of vasoprotective prostacyclin. The effects of 
calcitriol and a vitamin D analog such as paricalcitol on vascular 
calcifications (VCs) have not been clearly documented. Becker 
and colleagues compared the effect of two VDR activators, pari-
calcitol and calcitriol, in an established model of atherogenesis, 
the ApoE knockout mouse, with and without partial renal abla-
tion. Sham-operated and uninephrectomized (UNX) mice were 
randomly allotted to treatment with solvent, calcitriol, or pari-
calcitol. Semithin (0.6 mm) sections of the aorta were analyzed by 
morphometry, immunohistochemistry, and Western blotting of 
key proteins involved in VC and growth. Compared with sham-
operated animals (5.6 ± 0.24), the wall-to-lumen ratio of the aorta 
was significantly higher in solvent- and calcitriol-treated UNX 
animals, but not in paricalcitol-treated UNX animals. Expres-
sion of transforming growth factor-b1 (TGF-b1) in aortic intima/
plaque was also significantly higher in UNX solvent and UNX 
calcitriol than in sham-operated and UNX paricalcitol animals 
(Figure). At the dose used, paricalcitol significantly reduced 
TGF-b expression in plaques. In contrast, calcitriol caused sig-
nificant vascular calcification and elevated expression of related 
proteins (BMP2, RANKL, and Runx2). Whether the difference 
between paricalcitol and calcitriol treatment in UNX animals 
is driven by the difference in serum phosphate or parathyroid 
hormone concentration, by intrinsic differences between the two 
compounds, or by other factors is unknown.
This study in UNX ApoE–/– mice supports the hypothesis 
that selective VDR activation by paricalcitol (compared with 
calcitriol) results in less plaque growth and calcification and 
confirms earlier observations of the differential effect of vitamin 
receptor activators on VC in uremic rats.1 More studies are 
needed before these concepts can be extrapolated to humans.2 
The extent to which the model of atherosclerotic plaques and 
the effect of vitamin D on VC can be extrapolated to humans 
is currently unknown.
Marc De Broe
1Kidney Int 2007; 72: 709–715. 2Kidney Int 2007; 72: 977–984.
TGF-b expression in the aorta (original magnification, ×400).
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Special delivery of polycystin-2  
to the cilium
Hoffmeister et al., J Cell Biol 2011; 192: 631–645; doi:10.1083/
jcb.201007050
All membrane proteins are synthesized in the endoplasmic 
reticulum (ER) and are then transported to the Golgi, where 
a large number of modifications occur (glycosylation, sulfa-
tion, phosphorylation, and so on). They first enter the cis-Golgi 
(closest to the ER) and eventually end up in the trans-Golgi, 
trafficking to the plasma membrane from there. Recently, 
Hoffmeister et al. studied the trafficking pattern of polycys-
tin-2, which is known to reside in the cilium and to identify 
the signals that direct specifically to the cilium, a specialized 
domain of the plasma membrane. Using deletion mutations, 
they found that two amino acids control the targeting of this 
protein to the plasma membrane. However, mutation of these 
amino acids did not disrupt the traffic to the cilium, indicat-
ing that the route to that organelle does not pass through the 
classical protein traffic pathway described above. The authors 
showed with further studies that polycystin-2 moves to the 
cis-Golgi from the ER, directly passing to the cilium from 
there without having to pass through the trans-Golgi. They 
also demonstrated that Smoothened, another important cili-
ary protein and the receptor for hedgehog, also goes to the 
cilium from the cis-Golgi without passing through the trans-
Golgi. Hence, it appears that proteins destined for the cilium 
are delivered by vesicles to the basal body directly from the 
cis-Golgi network. This remarkable finding adds to the many 
surprising findings accumulating about the function of the 
cilia, an organelle once thought to have function only in swim-
ming cells, but now shown to be at the center of many diseases, 
including most, if not all, cystic kidney diseases.
Qais Al-Awqati
Nephron generation  
and kidney growth during  
kidney development
Karner et al., Development 2011; 138: 1247–1257; doi:10.1242/dev.057646
During development of the kidney, as in other organs, a balance 
must be struck between progenitor-cell proliferation and differ-
entiation so that the proper kidney size and nephron number are 
attained at the same time. Upon invading the metanephric mes-
enchyme, the ureteric bud epithelium sends signals to stimulate 
the survival and proliferation of a population of metanephric 
mesenchyme progenitor cells. However, a bud-derived signal or 
signals cause a subset of these progenitors to differentiate into 
an epithelial structure known as a renal vesicle, which, after a 
series of morphogenic steps, will form a nephron. Each mouse 
kidney contains up to 20,000 nephrons (~1,000,000 in an adult 
human), all derived from an initial progenitor population of 
approximately 12,000 cells. The mechanisms that regulate the 
balance between expansion and differentiation of the nephron 
progenitor-cell population are poorly understood. Nephron 
formation requires the sequential activity of two Wnts: Wnt9b 
and Wnt4. Wnt9b secreted by the ureteric bud induces a sub-
set of the renal progenitor cells to aggregate and express Wnt4. 
In turn, Wnt4, signaling through the canonical Wnt/b-catenin 
pathway, induces these pretubular aggregates to transition into 
the epithelial structures known as renal vesicles. The progeni-
tor cells that undergo differentiation express not only Wnt4 but 
also other Wnt9b targets such as Pax8 and Fgf8, whereas the 
remaining ‘uninduced’ progenitors do not express these genes. 
These results suggested that Wnt9b is inactive in the proliferat-
ing/renewing progenitor cells, thereby preventing their differ-
entiation. Because the transcription factor Six2 is expressed in 
proliferating progenitors and its loss caused early differentia-
tion of the entire progenitor population in a Wnt9b-dependent 
manner, it was postulated that Six2 blocks the ability of cells to 
receive the Wnt9b signal. In their recent study, Karner et al. used 
a variety of approaches to clarify the interaction between Wnt9b 
and Six2. Surprisingly, they found that Wnt9b signals through 
b-catenin both to the proliferating progenitor cells and to the 
differentiating cell population (Figure), but with distinct cellular 
and molecular results. In the progenitors, it promotes renewal/
proliferation, whereas in the cells that will form the renal vesicle, 
it promotes differentiation. Wnt9b is able to induce these dispa-
rate responses (self-renewal versus differentiation) because the 
combination of b-catenin and Six2 causes progenitor renewal, 
whereas activation of b-catenin alone (or in combination with 
another factor) results in differentiation. These events are criti-
cally important in determining total nephron number, and thus 
highly relevant to a variety of kidney diseases. 
Juan Oliver
Renal progenitors and Wnt9b-mediated epithelial differentiation. In 
wild-type mice, the ureteric bud (dotted lines) is surrounded by renal 
progenitors (arrows), identified by Six2 staining (green, top), and cells 
that will become the renal vesicle. Both cell populations contain the 
Wnt9b-responsive genes Cited1 (green, middle) and amphiphysin (green, 
bottom). Sections were stained with antibodies against b-catenin (red) 
and counterstained with the nuclear marker To-Pro 3 (blue).
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